2137847-77-7
Chemical Structure
(S)-Canocapavir
Synonym(s): (S)-ZM-H1505R
- CAS No.: 2137847-77-7
- Formula:C27H21BrFN5O3
- Molecular Weight:562.39
IUPAC Name: (S)-2-(1-(4-bromophenyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl)-3-(2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)ethyl)oxazolidin-4-one
InChIKey: YGPZZDKSASSELG-SANMLTNESA-N
SMILES: O=C1NC2=CC=C(C=C2N1)CCN3[C@](OCC3=O)([H])C4=CN(C5=CC=C(C=C5)Br)N=C4C6=CC=C(C=C6)F
Biological Activity:
(S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished
production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-Canocapavir | (S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection. |
|||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Jia H, et al. Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial. BMC Med. 2023;21(1):98. Published 2023 Mar 16. [Content Brief]
- [2]. Zheng Y, et al. Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein. Viruses. 2023;15(5):1195. Published 2023 May 18. [Content Brief]
Keywords
